Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)

被引：0

作者：

Parnis, F. ^{[1
]}

Tombal, B. ^{[2
]}

Hussain, M. ^{[3
]}

Saad, F. ^{[4
]}

Fizazi, K. ^{[5
]}

Sternberg, C. N. ^{[6
]}

Crawford, E. D. ^{[7
]}

Kopyltsov, E. ^{[8
]}

Kalebasty, A. Rezazadeh ^{[9
]}

Alekseev, B. Y. ^{[10
]}

Montesa Pino, A. ^{[11
]}

Ye, D. ^{[12
]}

Melo Cruz, F. J. S. ^{[13
]}

Tammela, T. ^{[14
]}

Suzuki, H. ^{[15
]}

Joensuu, H. ^{[16
]}

Thiele, S. ^{[17
]}

Li, R. ^{[18
]}

Kuss, I. ^{[19
]}

Smith, M. ^{[20
]}

机构：

[1] Ashford Canc Ctr Res, Dept Med Oncol, Kurralta Pk, SA, Australia

[2] Catholic Univ Louvain, Div Urol IREC, Clin Univ St Luc, Brussels, Belgium

[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Sch Med, Chicago, IL 60611 USA

[4] Ctr Hosp Univ Montreal CRCHUM, Dept Urol, Montreal, PQ, Canada

[5] Inst Gustave Roussy, Dept Canc Med, Villejuif, France

[6] Weill Cornell Med, Div Hematol & Oncol, Belfer Res Bldg, New York, NY USA

[7] Univ Calif San Diego, Dept Urol, Sch Med, San Diego, CA USA

[8] OMSK Reg Oncol Ctr, Clin Oncol, Omsk, Russia

[9] Univ Calif Irvine, UCI Hlth, Hematol Oncol & Med Dept, Orange, FL USA

[10] PA Hertsen Moscow Oncol Res Inst, Oncol, Moscow, Russia

[11] Hosp Reg Univ Malaga Carlos Haya, Oncol, Malaga, Spain

[12] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[13] Janssen Cilag Farmaceut Ltd, Dept Med Oncol, Sao Paulo, Brazil

[14] Tampere Univ Hosp, Dept Med Oncol, Tampere, Finland

[15] Toho Univ, Med Ctr, Sakura Hosp, Dept Urol, Sakura, Japan

[16] HUCH Helsinki Univ Cent Hosp, Dept Oncol, Helsinki, Finland

[17] Bayer AG, Clin Dev Oncol Dept, Berlin, Germany

[18] Bayer Healthcare Pharmaceut Inc, Clin Stat US SBU Oncol, Whippany, NJ 07981 USA

[19] Bayer AG, Clin Dev SBU Oncol, Berlin, Germany

[20] Massachusetts Gen Hosp, Oncol, Boston, MA 02114 USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.10.210

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

173TIP

引用

页码：S1501 / S1502

页数：2

共 50 条

[1] ARASENS: A phase 3 trial of darolutamide in males with metastatic hormone-sensitive prostate cancer (mHSPC)
Tombal, B.
Saad, F.
Hussain, M.
Sternberg, C. N.
Fizazi, K.
Crawford, E. D.
Yamada, K.
Kappeler, C.
Kuss, I.
Smith, M. R.
ANNALS OF ONCOLOGY, 2017, 28
[2] ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).
Smith, Matthew Raymond
Saad, Fred
Hussain, Maha
Sternberg, Cora N.
Fizazi, Karim
Yamada, Karin Sayuri
Kappeler, Christian
Kuss, Iris
Tombal, Bertrand F.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[3] TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
Merseburger, Axel S.
Suttmann, Henrik
AKTUELLE UROLOGIE, 2021, 52 (02) : 155 - 160
[4] ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer (mHSPC).
Smith, Matthew Raymond
Saad, Fred
Hussain, Maha
Sternberg, Cora N.
Fizazi, Karim
Crawford, E. David
Yamada, Karin Sayuri
Kappeler, Christian
Kuss, Iris
Tombal, Bertrand F.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[5] Use of abiraterone for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Cathomas, R.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 130 - 130
[6] DISEASE BURDEN OF METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) IN CHINA
Yu, M.
Duan, X.
Wang, J.
Zhang, X. J.
Yu, F.
VALUE IN HEALTH, 2021, 24 : S39 - S40
[7] Recent developments in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
Schwentner, Christian
AKTUELLE UROLOGIE, 2022, 53 (01) : 31 - 36
[8] Genomic profiles and clinical outcomes to distinguish primary from secondary metastatic hormone-sensitive prostate cancer (mHSPC).
Nizialek, Emily
Lim, Su Jin
Wang, Hao
Velho, Pedro Isaacsson
Antonarakis, Emmanuel S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study.
Wang, Shanshan
Fu, Cheng
Zou, Qing
Li, Youyuan
He, Dalin
Wang, Shaogang
Wang, Hongkai
Smith, Matthew Raymond
Tombal, Bertrand F.
Hussain, Maha H. A.
Niu, Yi
Cai, Ling
Hu, Nan
Huang, Shiyun
Kapur, Shivani
Li, Rui
Kuss, Iris
Ye, Dingwei
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] Therapy Optimization in the Management of Metastatic Hormone-sensitive Prostate Cancer: Insights from the ARASENS Study
Merseburger, Axel S.
Chowdhury, Simon
Bahl, Amit
EUROPEAN UROLOGY, 2024, 86 (04) : 340 - 342

← 1 2 3 4 5 →